Naltrexone News and Research RSS Feed - Naltrexone News and Research

Naltrexone injections could reduce risk of relapse among opioid dependent individuals

Naltrexone injections could reduce risk of relapse among opioid dependent individuals

In a multicenter, randomized clinical trial, ex-prisoners who received six monthly injections of naltrexone--a long-acting medication that blocks opioid receptors in the brain--were significantly less likely to resume opioid use than those who received counseling and referrals to community treatment centers without naltrexone. [More]
Opioids could be dangerous, deadly at high doses

Opioids could be dangerous, deadly at high doses

Most people know that heroin is a dangerous drug, but its cousins, the legal, pharmaceutical opioids, such as codeine or hydrocodone, must be safe, right?Not so fast.Opioids—which include the illegal drug heroin as well as prescription medications, including hydrocodone (such as Vicodin), oxycodone (such as OxyContin and Percocet), morphine and codeine—can be dangerous, even deadly, at high doses. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
First patient enrolled in Phase 3 efficacy trial of CAM2038 for opioid dependence

First patient enrolled in Phase 3 efficacy trial of CAM2038 for opioid dependence

Braeburn Pharmaceuticals and Camurus announce that the first patient has been randomized in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent patients. CAM2038 medications are designed for long-acting weekly and monthly administration. [More]
Braeburn, Camurus announce FDA Fast Track designation for CAM2038 to treat opioid addiction

Braeburn, Camurus announce FDA Fast Track designation for CAM2038 to treat opioid addiction

Braeburn Pharmaceuticals and Camurus announced today that the U.S. Food and Drug Administration granted Fast Track designation for the CAM2038 weekly and monthly buprenorphine subcutaneous injection products under development for the treatment of opioid addiction. [More]
Drug that relieves opioid-induced constipation may help some cancer patients live longer

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival. [More]
FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans. [More]
New guideline on the use of prescription medications for treatment of opioid addiction

New guideline on the use of prescription medications for treatment of opioid addiction

Medications play an important role in managing patients with opioid use disorders, but there are not enough physicians with the knowledge and ability to use these often-complex treatments. [More]
Drug addiction expert uncovers molecular mechanisms that contribute to addiction resistance

Drug addiction expert uncovers molecular mechanisms that contribute to addiction resistance

Growing up in West Virginia, Jill Turner saw firsthand the kind of havoc that drug addiction can wreak. "I had a lot of friends who had very promising lives and promising careers ahead of them," the assistant professor in the South Carolina College of Pharmacy says, "but they ended up either overdosing or going to jail for drug-related stuff. It's one of the reasons I went into drug addiction research." [More]

Egalet announces top-line results from Egalet-002 study in moderate drinkers

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. [More]
New UCLA study finds Naltrexone drug as promising treatment for methamphetamine addiction

New UCLA study finds Naltrexone drug as promising treatment for methamphetamine addiction

A new study by UCLA researchers has found that Naltrexone, a drug used to treat alcoholism, may also be a promising treatment for addiction to methamphetamine. [More]
Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015. [More]
Study could lead to potential drug treatment for fighting addiction

Study could lead to potential drug treatment for fighting addiction

A research team led by the University of Colorado Boulder has discovered a mechanism in the brain that is key to making cocaine seem pleasurable, a finding that could lead to a drug treatment for fighting addiction. [More]
Endocrine Society issues guideline on prescribing drugs to manage obesity, promote weight loss

Endocrine Society issues guideline on prescribing drugs to manage obesity, promote weight loss

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on strategies for prescribing drugs to manage obesity and promote weight loss. [More]
Added benefit of nalmefene not proven for alcohol dependence

Added benefit of nalmefene not proven for alcohol dependence

Nalmefene (trade name Selincro) has been approved since February 2013 for people with alcohol dependence who currently drink a lot of alcohol, but who do not have physical withdrawal symptoms and who do not require immediate detoxification. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in this patient group. [More]
Findings show that blockade of OGF-OGFr interfacing influences diabetic wound healing

Findings show that blockade of OGF-OGFr interfacing influences diabetic wound healing

A major complication associated with diabetes is delayed cell replication in epithelium and skin. Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have reported the presence and function of the opioid growth factor (OGF) and its nuclear-associated receptor (OGFr) in skin. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]
Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

Up to 20 percent of Parkinson's disease (PD) patients and their families may confront a common but largely unrecognized challenge: the occurrence of impulse control disorders (ICDs) such as compulsive gambling, sexual behavior, eating, or spending. [More]
Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease (ALD) is one of the leading causes of death worldwide and also in the UK. As its name indicates this disease arises due to consuming excessive amounts of alcohol (80 g/day) over an extended period, normally 10-20 years. [More]
New prescription weight-loss medication combines antidepressant with addiction medication

New prescription weight-loss medication combines antidepressant with addiction medication

A new prescription weight-loss medication that combines a popular antidepressant with a medication for addiction will be reviewed by the Federal Drug Administration (FDA) for potential approval. [More]
Advertisement
Advertisement